Learning to Use Heparin, a History
Discovery
In the late 19th century, researchers attempted to produce a drug with a hemostatic effect by injecting a peptone and inducing the release of an anticoagulant. The water-soluble substance isolated from the liver was heparin, but no one knew it at the time. What unfolded over the next four decades would change the trajectory of anticoagulation treatment.
By 1915, the most prominent expert on coagulation was William Howell at John Hopkins. A young medical student named Jay McLean entered Howell’s lab. He was successful in isolating a phosphatide from the liver that was identified as an antithrombin and called “heparphosphatide.” This substance was renamed “heparin” in 1918. Researchers spent the next decade further purifying it without finding a human application.
A series of breakthroughs occurred in the early 1930s by three independent research teams in Toronto, Stockholm, and Copenhagen. In Toronto, the team of CH Best found that heparin could be isolated from the lung as well as the liver. In Stockholm, a purified heparin was developed. It was confirmed to be a sulfated glycosaminoglycan and successfully injected into the first human subjects. Also in Stockholm, Clarence Crafoord, an expert in embolectomies used heparin post-operatively to prevent thromboembolism.
In 1938, Irving S. Wright, a professor of clinical medicine at Columbia University fell ill with thrombophlebitis following an appendicitis operation. This personal experience led him to search for possible treatments. With knowledge and a theory, he secured a supply of heparin from Best in Toronto and successfully treated a patient with recurrent thrombophlebitis.